Company Profile

Augmenta Bioworks Inc
Profile last edited on: 10/10/22      CAGE: 7L0H6      UEI: E8CLP6Q5LH86

Business Identifier: Novel therapeutics for infectious diseases with unmet need: harnessing human immunity
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

3475 Edison Way Unit K
Menlo Park, CA 94025
   (650) 731-2842
Location: Single
Congr. District: 18
County: Santa Clara

Public Profile

Engaging a proprietary discovery platform to develop antibodies to existing and emerging viral and bacterial diseases, Augmenta Bioworks tackles discovery of new therapeutics by harnessing the most powerful force in the fight against disease: natural human immunity. The firm's developed technology pinpoints the protective immune response of individuals and translates those discoveries into therapies.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2019 1 NIH $221,719
Project Title: Fluorescent Chimeric Antigen Receptor T Cell (CAR-T) Reporter Assay

Key People / Management

  John Beaber -- Associate Director, Protein Engineering

  Abigail Damico -- Lab Manager

  Christopher Joseph Emig

  Robin Emig -- Director of Informatics

  Nick Mannhardt -- Software Engineer

  Marco A Mena -- Co-Founder and COO

  Adela Anne Vitug -- Lab Manager

Company News

There are no news available.